Last updated 3 months ago

A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

1000 patients around the world
Available in Panama, Spain, Brazil, Argentina, Mexico
GlaxoSmithKline
6Research sites
1000Patients around the world
This study is for people with
Lung cancer
Non-small cell lung carcinoma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Centro Médico Privado CEMAIC - Córdoba
Centro Médico Privado CEMAIC - Córdoba
Recruiting
Monseñor Pablo Cabrera 2941, Córdoba
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Viamonte 2278, CABA, Buenos Aires
CEMER Centro Médico de Enfermedades Respiratorias - Vicente Lopez
Recruiting
Esmeralda 1550, Vicente Lopez, Buenos Aires
Centro Oncológico de Integración Regional C.O.I.R.
Recruiting
Monte Caseros 1020, Mendoza
Sanatorio 9 de Julio - Tucumán
Sanatorio 9 de Julio - Tucumán
Recruiting
San Juan 537, San Miguel de Tucumán, CP 4000
Centro Oncológico Korben
Recruiting
Cdad. de La Paz 353, C1426 CABA, Argentina
Trialtech
About usOur missionOur teamPartnersFAQs
Medical newsLatest newsStudiesInterviewsTestimonials
ProductsUEPM OncoUEPM Physicians
LinksDownloads
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy